Angiogen LLC

1
ANGIOGEN LLC

• Gerald A. Soff M.D.
• Mark G. Arizmendi

2
Angiogen LLC

• Angiogen is a Chicago based biotechnology firm
• Founded to developing novel cancer therapies
  using FDA approved drugs in an Angiostatic
  Cocktail
• Angiogenesis Inhibitor therapies for cancer are
  scientifically proven and sound
• 4.0 billion in Research and Development has
  attracted 200 biotech and pharmaceutical
  companies
• Clinical trials are supported by Genentech
• Broad patent coverage
• Angiogens therapy produces the desired protein
  to inhibit cancer in vivo

3
Cancer Statistics

• Approximately 1.3 million people are diagnosed
  with cancer in the United States each year
• Approximately 50 of those diagnosed have solid
  tumors
• Approximately 550,000 people in the US die
  annually from metastatic cancer

4
Existing Cancer Therapies

• Typical approach combination of chemotherapy,
  radiation, surgery
• Surgery is invasive
• Chemotherapy and radiation have severe side
  effects
• Varying degrees of effectiveness
• Mortality rates are high in advanced cases

5
Scientific Overview Angiogenesis

• New blood vessel formation
• Induction of a new blood supply
• Promoted by growth factors
• Focal point of ongoing cancer research

6
The Competitions Approach to Vascular Tumors

• Targeting vascular endothelial growth factor
  (VEGF)
• VEGF is emitted by oxygen deprived cells and
  mutating cancer cells
• Potential resistance to VEGF therapy
• Other growth factors
• Selective targeting (the needle in a haystack)
• Failed trials and recombinant proteins in vitro

7
Angiogens Approach

• Angiostatin is a proven and potent angiogenesis
  inhibitor
• Angiogens cocktail produces Angiostatin4.5 is
  produced naturally in vivo
• Angiogen combines existing FDA approved drugs in
  a novel Cocktail
• FDA approvals may be quicker
• Broad based therapy

8
Angiogens Technique Target the Endothelial
Cells

• Angiostatin4.5 targets endothelial cells
• Endothelial cells naturally respond to
  Angiostatin
• Genetically normal
• Replicating the bodys own cancer fighting
  mechanism instead of exogenous production of
  inhibitory proteins

9
The Angiostatic Cocktail In Vivo Generation Of
Angiostatin4.5

• The key components of the Angiostatic Cocktail
• Tissue Plasminogen Activator or Urokinase
• Free Sulfhydryl Donor
• Angiostatin generated directly in the blood
• Replication of natural Angiostatin generation
• Angiogens broad patent

10
Preliminary Human Results With Angiostatic
Cocktail

• 2001 Pilot Study 8 patients
• Terminal cancer patients who had failed
  conventional radiation and chemotherapy
• A phase 1 trial has been completed at
  Northwestern to determine the optimal dose and
  schedule

11
Administration Of Angiostatic Cocktail Generates
Angiostatin In The Blood Of Cancer Patients
12
Angiogens Advantage

• Transforming Technology
• Only one competitive anti-angiogenic drug has
  been approved
• Angiogen is directly targeting the endothelial
  cells
• Pervasive therapy
• Potentially Short Time To Commercial Success.
• FDA approved agents are used in the Angiostatic
  Cocktail
• Angiogen has to show efficacy of the Cocktail
• The FDA does not recognize the cocktail as a new
  chemical entity. Good manufacturing processes
  and safety are already proven.

13
Angiogens Advantage

• The founder is world renowned in
  anti-angiogenesis research and application
• Angiogen has a broad patent
• The main Phase I trial is underway
• The preliminary Phase I trial elicited positive
  data
• Genentech and Northwestern University support
• Broad range of metastatic cancer with a large
  potential market

14
Does it Work? Case Study 1 14 Yr Girl With
Ewings Sarcoma

• A 14 year old girl, with relapsed Ewings
  Sarcoma, was treated with the Angiostatic
  Cocktail
• The girl had failed all conventional therapy
  (chemo, radiation, transplant)
• Was treated with the Angiostatic Cocktail and
  achieved a complete remission
• Relapsed due to inability to continue treatment

15
CT ScansA 14 Yr Girl With Ewings Sarcoma
6 Weeks of Treatment (Tumor Liquefaction)
Prior to Treatment
At 12 Weeks. No Evidence Of Disease.
16
Valuation and Capitalization

• Angiogen is seeking 5,000,000 in 2004 for
  Research and Development expenses for the next 2
  years
• These funds will allow Angiogen to develop the
  Angiostatic Cocktail
• Licensure will be made when optimal for
  investors and The Company

17
Projected Timeline and Milestones

• 1996 Original patent application filed
• 1998 First patent granted
• 1999 Angiogen LLC formed
• 1998-2001 The Angiostatic Cocktail is
  administered to patients on a compassionate use
  basis
• 2001-2003 Preliminary Phase I
• 2003 Second patent granted
• 2004 Phase I commenced at Northwestern
  University Memorial Hospital
• 2005-2006 Phase II expected to commence
• 2006-2007 Phase III begins, if necessary
• 2007 Angiogen intends to sign a licensing
  agreement or merge with a major biotech or
  pharmaceutical company

18
Pro Forma Income Statement

• All dollars amounts in thousands
• 2003 2004 2005 2006 2007 2008
• Revenue 0 0 900 900
  7,413 24,640
• COGS 0 107 270 3,381 13,249 19,324
• Operating Expense 0 202 369 766
  1,430 2,324
• Pre-Tax Net Income 0 ( 309)
  261 (3,247) ( 7,266) 2,992